Physician profile
Nathan M DO
NPI 1649346230
$18,433.01
in general payments reported to CMS, 2019-2025
40 companies · $3,489 in 2025
The $3,489 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,347 · 2020: $1,952 · 2021: $2,003 · 2022: $1,373 · 2023: $2,166 · 2024: $5,103 · 2025: $3,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,871 · Education: $3,381 · Travel and Lodging: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,870.87 |
| Education | $3,381.49 |
| Travel and Lodging | $1,506.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,898.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,187.75 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,255.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,776.15 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pulmonx Corporation | $1,022.79 | 2019-2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.65 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Genzyme Corporation | $595.62 | 2020-2024 | |
| Insmed, INC. | $582.10 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $533.72 | 2020-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $386.42 | 2019-2024 | |
| United Therapeutics Corporation | $333.65 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $321.48 | 2023-2025 | Winrevair, Belsomra |
| Amgen INC. | $233.24 | 2022-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $162.23 | 2019-2024 | Dupixent |
| Philips North America LLC | $153.77 | 2019-2024 | (Ae4) Secretion Management |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $142.96 | 2020-2024 | |
| Pfizer INC. | $110.74 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $109.39 | 2023-2025 | Acthar |
| Mylan Specialty L.P. | $105.89 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $93.43 | 2020-2024 | |
| Gilead Sciences, INC. | $93.01 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $73.10 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $72.70 | 2019-2021 | |
| Grifols USA, LLC | $62.14 | 2023-2025 | Prolastin-C Liquid |
| Sandoz INC. | $59.43 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $59.16 | 2020-2023 | Nuzyra |
| Inogen, INC. | $48.34 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Takeda Pharmaceuticals U.S.A., INC. | $46.98 | 2021 | |
| Baxter Healthcare | $42.35 | 2024-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Idorsia Pharmaceuticals US INC | $37.22 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $25.64 | 2020-2021 | |
| Circassia INC. | $24.17 | 2019 | |
| Verona Pharma, INC. | $24.05 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $23.87 | 2023 | Lumryz |
| Resmed Corp | $23.27 | 2023 | |
| Optinose US, INC. | $22.70 | 2022 | |
| Liquidia Technologies, INC. | $21.15 | 2025 | Yutrepia |
| Vanda Pharmaceuticals INC. | $21.14 | 2021 | |
| Electromed, INC. | $20.81 | 2023 | Smartvest |
| Shire North American Group INC | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.